Maxygen’s board approved a second and final liquidating distribution of $0.09 per share, to be paid on or about June 30. Shareholders received an initial payout of $69.5 million, or about $2.50 per share, after...

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...

Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen said it could...

Maxygen said its board approved a plan to liquidate and dissolve the company. The estimated shareholder payout is about $68.2-$69.6 million, or about $2.45-$2.50 per share based on 27.8 million shares outstanding as of May...

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...

Maxygen Inc., Santa Clara, Calif.   Business: Enabling technology   Hired: Alejandro Zaffaroni, Ph.D., as CEO, currently a director at Affymax Research Institute (Palo Alto, Calif.); Russell Howard, Ph.D., as president and COO; formerly president...

Maxygen will receive a $30 million milestone payment from Bayer's Bayer HealthCare LLC subsidiary under a 2008 deal in which the pharma acquired Maxygen's hemophilia program. The payment was triggered by undisclosed clinical development of...

Regulatory milestones Osiris Therapeutics Inc. (NASDAQ:OSIR) gained $0.25 to $5.55 last week after Health Canada granted Prochymal conditional approval to treat acute graft-versus-host disease (GvHD) in children. Prochymal is an IV formulation of mesenchymal stem...

Maxygen said its board approved a share repurchase program for up to $10 million through Dec. 31. Maxygen, which closed Friday at $5.51, has 28.1 million shares outstanding. Maxygen Inc. (NASDAQ:MAXY), Redwood City, Calif.  ...

Maxygen said HHS's Biomedical Advanced Research and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen said BARDA found its proposal "technically sound" but raised concerns about the dependence...